Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
NH, AZ Authorize Crypto Reserves Two months after President Trump signed an executive order establishing a federal strategic bitcoin reserve and digital asset stockpile, New Hampshire and Arizona have...
FL Condo Bill Raises Insurance Concerns Florida lawmakers passed a bill ( HB 913 ) intended to provide condominium owners some relief from the high cost of bringing properties up to code, as a result...
State Lawmakers Shift from PBMs to PSAOs in Fight Against High Drug Costs For a while now state legislators have targeted pharmacy benefit managers, or PBMs, for contributing to the high cost of prescription...
TX Taking Tougher Stance on Social Media for Kids The Texas House passed a bill ( HB 186 ) that would ban social media accounts for anyone under the age of 18. The measure would also allow parents to...
IA Enacts Law Addressing Shortage of Birth Centers Iowa Gov. Kim Reynolds (R) signed a bill ( HF 887 ) exempting freestanding birth centers from having to obtain a certificate of need from the state’s...
California joined a nationwide movement to tighten restrictions on pharmacy benefit managers with the approval of SB 966 days before adjourning its legislative session on Aug. 31. If signed by Gov. Gavin Newsom (D) the measure will establish licensing requirements for PBMs and require them to report to the state’s Department of Insurance the fees they charge pharmacies and the rebates they receive from drug manufacturers. The bill would also require PBMs to pass along 100% of those rebates to health plans or insurers. (PLURIBUS NEWS, LEXISNEXIS STATE NET)
In 2021, Arkansas became the first state to pass a law requiring pharmaceutical manufacturers that participate in Medicaid to sell drugs to contract pharmacies at a discount under the federal 340B program. Louisiana followed suit in 2023. This year, Kansas (SB 28), Maryland (HB 1056), Mississippi (HB 728), Missouri (SB 751) and West Virginia (SB 325) enacted similar legislation. And other states, including New York (AB 7789), considered similar measures.
The recent legislative actions are pushback against the restriction of 340B drug sales by pharmaceutical companies, which contend the 340B program has expanded beyond its original intent. As of September 2023, 25 drugmakers had done so. (STATELINE)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.